dendreon biotechnology company lead product provenge known generically sipuleucelt immunotherapy prostate cancer consists mixture patients blood cells autologous dendritic cells thought important incubated dendreon papgmcsf fusion protein phase iii clinical trial results demonstrating survival benefit prostate cancer patients receiving drug presented aua meeting april going approval process provenge given full approval fda april dendreons stock value fell august abandoning forecast debut drug november dendreon filed chapter bankruptcy protection shortly afterwards announced reached agreements terms financial restructuring certain bond february valeant pharmaceuticals received approval purchase dendreon assets january sanpower group agrees acquire dendreon valeant million june sanpower group chinese conglomerate purchased dendreon valeant dendreons name derives dendritic cell forms major component companys product candidates use dendreon cassette technology insert diseasespecific target protein general platform lead product provenge example rationally designed therapeutic process intended break immune tolerance certain disease specific proteins hypothesized receptor mediated uptake antigen dendritic cells occurs exposed dendreon fusion protein links disease specific protein recognition protein approach contrast dendritic cell vaccines use methods electroporation get dcs present antigen related epitopes case provenge disease related protein prostatic acid phosphatase signalling component gmcsf dendreon believes process optimized generalized diseases exchanging pap component provenge better targets specific different diseased antigen selection significant issue cancer vaccines general presumably therapeutic effect obtained provoking selective response diseased cells dendreon explored approaches obtaining tumourspecific antigen targets theory immune system may able mount effective response otherwise possible tumor associated antigens unaltered human pap expressed normal prostate cells recent discoveries suggest cancer cells produce many unique targets well proteins highly expressed normal also recently discovered enzymes expressed nerves identical ongoing work examine posttranslational modifications pap correlation disease state dendreon pap also appears expressed breast prior work area also included sette epimmune altered peptide ligand approach typified neurocrine biotechs failed ms drug dendreon acquired nematode anticoagulant selected corvas patents include technologies peptide analog synthesis drugs target coagulation immune processes drs haseltine engleman strober established company initially named activated cell therapy mountain view california securing funding health care ventures edison new jersey company successfully brought market first approved cellbased immune therapy provenge treatment metastatic prostate several years company changed name dendreon moved seattle washington christopher henney initial clinical results provenge showed immune responses supporting expected modeofaction well psa reduction thought relate clinical dendreon built manufacturing facility morris plains new jersey accommodate production phase iii trial possible drug approval us food drug administration january fda accepted dendreons biologic license application bla filing march fda office cellular tissue gene therapies advisory committee voted provenge reasonably safe trial data showed substantial evidence however may dendreon received letter fda demanding results information april dendreon announced results phase iii trial provenge positive saying reduction odds death compared use april full details study released trial found patients treated provenge lived average months longer patients treated control autologous cells without gmcsf pap fusion april fda approved provenge use treatment advanced prostate cancer june head medicares coverage analysis group dr louis jacques sent three colleagues email telling sure leak fact group considering cap medicare coverage treatment news caution inevitably leak price dendreons stock fell later day journalists referred provenge supporters dendreonites name routine usage colloquial concerns personal safety raised among doctors thought responsible delay provenge dendreonites questioned doctors objectivity one dr howard scher lead clinical trial investigator rival prostate cancer drug biotech company concerns motivated organized protests fda american society clinical oncology asco meeting various patient investor advocacy groups also filed lawsuit alleging fdas decision influenced conflicts httpsenwikipediaorgwikidendreon